At under US$1,000, Hypernova isn’t just eyewear—it’s Meta’s push to make AR feel ordinary.
Updated
January 8, 2026 6:34 PM
Closeup of the Ray-Ban logo and the built-in ultra-wide 12 MP camera on a pair of new Ray-Ban Meta Wayfarer smart glasses. PHOTO: ADOBE STOCK
Meta is preparing to launch its next big wearable: the Hypernova smart glasses. Unlike earlier experiments like the Ray-Ban Stories, these new glasses promise more advanced features at a price point under US$1,000. With a launch set for September 17 at Meta’s annual Connect conference, the Hypernova is already drawing attention for blending design, technology and accessibility.
In this article, let’s take a closer look at Hypernova’s design, features, pricing and the challenges Meta faces as it tries to bring smart glasses into everyday life.
Meta’s earlier Ray-Ban glasses offered cameras and audio but no display. Hypernova changes that: The glasses will ship with a built-in micro-display, giving wearers quick access to maps, messages, notifications and even Meta’s AI assistant. It’s a step toward everyday AR that feels useful and natural, not experimental.
Perhaps most importantly, the price makes them attainable. While early estimates placed the cost above US$1,000, Meta has committed to a launch price of around US$800. That’s still premium, but it moves AR smart glasses into reach for more consumers.
Hypernova weighs about 70 grams, roughly 20 grams heavier than the Ray-Ban Meta models. The added weight likely comes from added components like the new display and extra sensors.
To keep the glasses stylish, Meta continues its partnership with EssilorLuxottica, the company behind Ray-Ban and Prada eyewear. Thicker frames—especially Prada’s designs—help hide the hardware like chips, microphones and batteries without making the glasses look oversized.
The glasses stick close to the classic Ray-Ban silhouette but feature slightly bulkier arms. On the left side, a touch-sensitive bar lets users control functions with taps and swipes. For example, a two-finger tap can trigger a photo or start video recording.
Hypernova introduces something the earlier Ray-Ban glasses never had: a display built right into the lens. In the bottom-right corner of the right lens, a small micro-screen uses waveguide optics to project a digital overlay with about a 20° field of view. This means you can glance at turn-by-turn directions, check a notification or quickly consult Meta’s AI assistant without pulling out your phone. It’s discreet, practical and a major step up from the older models, which were limited to capturing photos and videos, handling calls and playing music via speakers.
Alongside the glasses comes the Ceres wristband, a companion device powered by electromyography (EMG). The band picks up the tiny electrical signals in your wrist and fingers, translating them into commands. A pinch might let you select something, a wrist flick could scroll a page, and a swipe could move between screens. The idea is to avoid clunky buttons or having to talk to your glasses in public. Meta has also been experimenting with handwriting recognition through the band, though it’s not clear if that feature will be ready in time for launch.
Meta doesn’t just want Hypernova to be useful—it wants it to be fun. Code found in leaked firmware revealed a small game called Hypertrail. It looks to borrow ideas from the 1981 arcade shooter Galaga, letting wearers play a simple, retro-inspired game right through their glasses. It’s not the main attraction, but it shows Meta is trying to make Hypernova feel more like a playful everyday gadget rather than just a piece of serious tech.
Hypernova runs on a customized version of Android and pairs with smartphones through the Meta View app. Out of the box, it should support the basics: calls, music and message notifications. Leaks suggest several apps will come preinstalled, including Camera, Gallery, Maps, WhatsApp, Messenger and Meta AI. A Qualcomm processor powers the whole setup, helping it run smoothly while keeping energy demands reasonable.
Meta is also trying to bring in outside developers. In August 2025, CNBC reported that the company invited third-party developers—especially in generative AI—to build experimental apps for Hypernova and the Ceres wristband. The Meta Connect 2025 agenda even highlights sessions on a new smart glasses SDK and toolkit. The push shows Meta’s interest in making Hypernova more than just a device; it wants a broader platform with apps that go beyond its own first-party software.
During development, Hypernova was rumored to cost as much as US$1,400. By pricing it around US$800, Meta signals that it wants adoption more than profit. The company is keeping production limited (around 150,000 units), showing it sees this as a market test rather than a mass rollout. Still, the sub-US$1,000 price tag makes advanced AR far more accessible than before.
Despite its promise, Hypernova may still face hurdles. The Ceres wristband can struggle if worn loosely, and some testers have reported issues based on which arm it’s worn on or even when wearing long sleeves. In short, getting EMG input right for everyone will be critical.
Privacy is another major concern. In past experiments, researchers hacked Ray-Ban Meta glasses to run facial recognition, instantly identifying strangers and pulling personal info. Meta has added guidelines, like a recording indicator light, but critics argue these measures are too easy to ignore. Moreover, data captured by smart glasses can feed into AI training, raising questions about consent and surveillance.
The Meta Hypernova smart glasses mark a turning point in wearable tech. They’re lighter and more stylish than bulky AR headsets, while offering real-world features like navigation, messaging and hands-free control. At under US$1,000, they aim to make AR glasses more than a luxury gadget—they’re a step toward everyday use.
Whether Hypernova succeeds will depend on how well it balances style, usability and privacy. But one thing is clear: Meta is betting that always-on, glanceable AR can move from science fiction to daily life.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.